RxDoctor Payments Data

Bryan Leatherman, MD

Otolaryngic Allergy · Gulfport, MSNPI 1154367738

Payments from drug & device makers

$21,309in general payments, 2019–2025

Across 98 payments — averaging $217.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Sanofi$2K
  • GSK$325
  • Regeneron Healthcare Solutions, Inc.$313
  • Optinose US, Inc.$200
  • Aerin Medical Inc.$125
  • plus $237 from 5 others

What the payments were for

  • Consulting fees$5,47626%
  • Speaking & faculty fees$11,60054%
  • Travel & lodging$1,2216%
  • Food & beverage$2,53212%
  • Education$4802%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otolaryngic allergy providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$138,937
Medicare patients
630
Services billed
2,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$40,741
Ipratropium Bromide525$18,131
Fluticasone Propionate865$13,258
Famotidine416$3,886
Arnuity ElliptaFluticasone Furoate12$3,048
Ofloxacin57$2,120
Pantoprazole Sodium311$2,040
Clobetasol Propionate88$2,038
Ketorolac Tromethamine26$1,369
Azelastine Hcl44$1,329
Pilocarpine Hcl20$1,210
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort13$748
Mupirocin30$491
Doxycycline Hyclate42$449
Clindamycin Phosphate16$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$325$3,04812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngic allergy providers in Mississippion file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →